Cancer Science · 2022 · 11 citations · 36 references
MedicineCancer BiologyOncologyGene ExpressionMolecular OncologyTranscriptional RegulationCancer Cell SignalingCyclin-dependent KinasesEnhancer FunctionHematologic Malignancy TherapyOncogenic ProliferationTumor Suppressor GenesCdk InhibitorsChromatin Immunoprecipitation SequencingCyclin-dependent Kinase 9Cyclin-dependent Kinase PhosphorylationNeoplastic DiseaseSuper-enhancer FunctionSuper-enhancer InteractionsSuper-enhancer Regulation
Adult T-cell leukemia/lymphoma (ATL) is an intractable hematological malignancy with extremely poor prognosis. Recent studies have revealed that super-enhancers (SE) play important roles in controlling tumor-specific gene expression and are potential therapeutic targets for neoplastic diseases including ATL. Cyclin-dependent protein kinase (CDK) 9 is a component of a complex comprising transcription factors (TFs) that bind the SE region. Alvocidib is a CDK9 inhibitor that exerts antitumor activity by inhibiting RNA polymerase (Pol) II phosphorylation and suppressing SE-mediated, tumor-specific gene expression. The present study demonstrated that alvocidib inhibited the proliferation of ATL cell lines and tumor cells from patients with ATL. RNA sequencing (RNA-Seq) and chromatin immunoprecipitation sequencing (ChIP-Seq) disclosed that SE regulated IRF4 in the ATL cell lines. Previous studies showed that IRF4 suppression inhibited ATL cell proliferation. Hence, IRF4 is a putative alvocidib target in ATL therapy. The present study revealed that SE-mediated IRF4 downregulation is a possible mechanism by which alvocidib inhibits ATL proliferation. Alvocidib also suppressed ATL in a mouse xenograft model. Hence, the present work demonstrated that alvocidib has therapeutic efficacy against ATL and partially elucidated its mode of action. It also showed that alvocidib is promising for the clinical treatment of ATL and perhaps other malignancies and neoplasms as well.
36
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
PubMed · 1997 · 66.6K citations
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Warren A. Whyte, David A. Orlando, Denes Hnisz et al. · Cell · 2013 · 4.3K citations · Full text
Super-Enhancers in the Control of Cell Identity and Disease
Denes Hnisz, Brian J. Abraham, Tong Ihn Lee et al. · Cell · 2013 · 3.9K citations · Full text
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Tsuneo Uchiyama, Junji Yodoi, Kimitaka Sagawa et al. · Blood · 1977 · 2.1K citations
Medicine, Hematology, Oncology +14